Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.

Raquel Deering, one of In Vivo's 2020 Rising Leaders, discusses Regeneron's efforts to develop combination therapies, its collaborations with cancer vaccine companies, and its plans to become a major force in the oncology field.

Company keeps on track on for 2020 earnings target despite pandemic's hit to general medicines and vaccines sales.

As it prepares to report second quarter earnings that may show coronavirus-related impacts, the company’s antiviral for COVID-19 may boost 2020 revenue and offset need for new products.